B P Monia

Summary

Affiliation: Isis Pharmaceuticals
Country: USA

Publications

  1. ncbi Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo
    B P Monia
    Isis Pharmaceuticals, Carlsbad, CA 92008, USA
    Proc Natl Acad Sci U S A 93:15481-4. 1996
  2. ncbi Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma
    J G Karras
    Departments of Molecular and Cellular Pharmacology and Pharmacology, Isis Pharmaceuticals, Carlsbad, CA 92008, USA
    J Immunol 164:5409-15. 2000
  3. ncbi Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development
    J T Holmlund
    Isis Pharmaceuticals Inc, Carlsbad, CA 92008, USA
    Curr Opin Mol Ther 1:372-85. 1999
  4. ncbi Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes
    S T Crooke
    Isis Pharmaceuticals, Inc, Carlsbad, CA 92008, USA
    Biochem J 312:599-608. 1995
  5. ncbi Elucidating cell signaling mechanisms using antisense technology
    E Koller
    Department of Molecular and Cellular Pharmacology, Isis Pharmaceuticals, Carlsbad, CA 92008, USA
    Trends Pharmacol Sci 21:142-8. 2000
  6. ncbi Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing
    J G Karras
    Department of Molecular and Cellular Pharmacology, Isis Pharmaceuticals, Carlsbad, California 92008, USA
    Mol Pharmacol 58:380-7. 2000

Collaborators

Detail Information

Publications6

  1. ncbi Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo
    B P Monia
    Isis Pharmaceuticals, Carlsbad, CA 92008, USA
    Proc Natl Acad Sci U S A 93:15481-4. 1996
    ..e., antisense) mechanism of action. These results provide important experimental evidence supporting an antisense mechanism of action underlying the in vivo antitumor activity displayed by ISIS 5132 or CGP69846A...
  2. ncbi Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma
    J G Karras
    Departments of Molecular and Cellular Pharmacology and Pharmacology, Isis Pharmaceuticals, Carlsbad, CA 92008, USA
    J Immunol 164:5409-15. 2000
    ..These data underscore the potential utility of an antisense approach targeting IL-5 for the treatment of asthma and eosinophilic diseases...
  3. ncbi Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development
    J T Holmlund
    Isis Pharmaceuticals Inc, Carlsbad, CA 92008, USA
    Curr Opin Mol Ther 1:372-85. 1999
    ..This review summarizes the status of development of three anticancer antisense oligonucleotides from ISIS Pharmaceuticals...
  4. ncbi Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes
    S T Crooke
    Isis Pharmaceuticals, Inc, Carlsbad, CA 92008, USA
    Biochem J 312:599-608. 1995
    ..Multiple deoxynucleotide gaps increased the Vmax. but had little effect on Km. 3. The effects of several base modifications on the site of initial cleavage, processivity and initial rate of cleavage were also studied...
  5. ncbi Elucidating cell signaling mechanisms using antisense technology
    E Koller
    Department of Molecular and Cellular Pharmacology, Isis Pharmaceuticals, Carlsbad, CA 92008, USA
    Trends Pharmacol Sci 21:142-8. 2000
    ..This article reviews the opportunities that antisense oligonucleotides offer for the study of signal transduction pathways and identification of inhibitors of these pathways for drug development...
  6. ncbi Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing
    J G Karras
    Department of Molecular and Cellular Pharmacology, Isis Pharmaceuticals, Carlsbad, California 92008, USA
    Mol Pharmacol 58:380-7. 2000
    ....